Researchers at the Institute of Molecular and Clinical Ophthalmology Basel have created MitoCatch, a technology that delivers healthy mitochondria directly to damaged cells. This method targets diseases caused by mitochondrial dysfunction, such as Parkinson's and optic nerve degeneration, by using engineered protein binders to guide mitochondria to specific cell types. Early tests show improved cell survival and recovery without immune reactions in animal models, marking a significant advance toward precision mitochondrial medicine. The technology could transform treatment options for currently untreatable mitochondrial diseases.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
Forum Markets has acquired a commercial aircraft engine for about $12 million, increasing its aviation portfolio to four engines leased to major U.S. airlines. The engine, a widely used CFM56-7B model, is already generating revenue under a long-term ...
